Have Any Questions?


Your Current Position:Home >> About >> Management Team

Xueming Qian, Ph.D., Founder,Chairman & CEO
Dr. Qian has over eighteen years of industrial antibody discovery and development experience. Before starting MABSPACE, Dr. Qian was Senior VP and Head of R&D of Shenogen Pharma Group from 2010 and 2012; a Beijing-based biopharma company developing ER-a36 based anti-cancer therapies. From 1997 and 2010 Dr. Qian worked at Amgen as principal scientist and led multiple project teams to discover novel antibody therapeutics for the autoimmune diseases and metabolic disorders (bone and kidney). He is the leading inventor of multiple antibody patents.Dr. Qian graduated from Fudan University and completed his graduate studies at Columbia University and Albany Medical Center.  He is a member of Antibody Society, International Society of Nephrology and BayHelixa member of National Thousand Talents program.





Li Zhen, Executive Director, Antibody Discovery & Preclinical Development 
Mr. Li is currently responsible for the antibody discovery and preclinical development of antibody based therapeutics at MabSpace. Mr. Li joined MabSpace in 2013 with more than 12 years industry experience of drug discovery and preclinical development. Before joining MabSpace, he was preclinical development project leaders in Shenogen Pharma, Hutchison Biopharma and Luye Pharma. He was involved in the preclinical study of various novel drugs, including Icaritin and ER-a36 targeting antibody, EGFR/c-Met /RON small molecular TKIs, sustained release microsphere projects at Luye.

Junjie Lisa Zheng, Senior Director,Process Development
Lisa has over 20 years working experience at Genentech where she mainly focused on cell line development, Phase I/III process development and tech transfer for many therapeutic antibody projects. She also supported CMC activities, IND filing, GMP manufacture campaigns, and BLA filing. She is an author for a book chapter publication and fourteen peer-reviewed journal publications. 
Guangliang Greg Pan, Ph.D., Senior Vice President, Head of CMC
He is currently the Vice President of MabSpace Biosciences heading CMC development. Dr. Pan has been involved in biologics drug product development and manufacturing for the past fourteen years. Dr. Pan accumulated extensive experience in biologics development and manufacturing during his employment with several internationally renowned biopharmaceutical companies. Prior to MabSpace, he was a senior biologics outsourcing manager and technical leader at Gilead Sciences. He was a principal research scientist at Lilly before he joined Gilead Science in 2014. During his tenure with Eli Lilly (2007-2014), he was a technical leader leading early and late phase protein drug product development and manufacturing. Before joining Eli Lilly in 2007 he was a senior research scientist at Novartis. Before Novartis,he joined Imclone as a senior scientist in 2004 and later promoted to manager and senior manager in monoclonal antibody formulation and analytical development. Dr. Pan graduated from Shandong University with BS degree in Bioengineering. He received his Ph.D. in pharmaceutics from the University of Georgia and completed his postdoctoral research in peptide transdermal delivery at Johnson and Johnson. He is a member of American Association of Pharmaceutical Sciences (AAPS), Parenteral Drug Association (PDA).

Copyright © 2017 Mabspace Biosciences All rights reserved